Skip to main content

AmoyDx, Janssen Research and Development Partner on NGS-Based Companion Diagnostic

NEW YORK — AmoyDx said on Tuesday that it has partnered with Janssen Research and Development to develop a next-generation sequencing-based companion diagnostic for the Chinese market.

Under the terms of the deal, Xiamen, China-based AmoyDx will develop and secure Chinese regulatory approval for its LC10 Essential NGS panel as a companion diagnostic to an undisclosed cancer therapy.

Additional terms were not disclosed.

In late 2018, AmoyDx received approval from the Chinese National Medical Products Administration for the Essential NGS panel for the detection of gene mutations in non-small cell lung cancer and colorectal cancer patients.

Earlier this month, Janssen Research and Development, a Johnson & Johnson company, signed an agreement to develop a companion diagnostic based on Thermo Fisher Scientific's Oncomine Dx Target Test to support clinical trial enrollment of cancer patients.